Neutrophil degranulation interconnects over-represented biological processes in atrial fibrillation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
03 02 2021
Historique:
received: 24 06 2020
accepted: 18 01 2021
entrez: 4 2 2021
pubmed: 5 2 2021
medline: 16 11 2021
Statut: epublish

Résumé

Despite our expanding knowledge about the mechanism underlying atrial fibrillation (AF), the interplay between the biological events underlying AF remains incompletely understood. This study aimed to identify the functionally enriched gene-sets in AF and capture their interconnection via pivotal factors, that may drive or be driven by AF. Global abundance of the proteins in the left atrium of AF patients compared to control patients (n = 3/group), and the functionally enriched biological processes in AF were determined by mass-spectrometry and gene set enrichment analysis, respectively. The data were validated in an independent cohort (n = 19-20/group). In AF, the gene-sets of innate immune system, metabolic process, cellular component disassembly and ion homeostasis were up-regulated, while the gene-set of ciliogenesis was down-regulated. The innate immune system was over-represented by neutrophil degranulation, the components of which were extensively shared by other gene-sets altered in AF. In the independent cohort, an activated form of neutrophils was more present in the left atrium of AF patients with the increased gene expression of neutrophil granules. MYH10, required for ciliogenesis, was decreased in the atrial fibroblasts of AF patients. We report the increased neutrophil degranulation appears to play a pivotal role, and affects multiple biological processes altered in AF.

Identifiants

pubmed: 33536523
doi: 10.1038/s41598-021-82533-5
pii: 10.1038/s41598-021-82533-5
pmc: PMC7859227
doi:

Substances chimiques

Nonmuscle Myosin Type IIB EC 3.6.1.-
nonmuscle myosin type IIB heavy chain EC 3.6.1.-
Myosin Heavy Chains EC 3.6.4.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2972

Subventions

Organisme : ZonMw
ID : 016.146.310
Pays : Netherlands

Références

Benjamin, E. J. et al. Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation 98(10), 946–952 (1998).
pubmed: 9737513 doi: 10.1161/01.CIR.98.10.946
Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114(2), 119–125 (2006).
pubmed: 16818816 doi: 10.1161/CIRCULATIONAHA.105.595140
Heijman, J., Guichard, J. B., Dobrev, D. & Nattel, S. Translational challenges in atrial fibrillation. Circ. Res. 122(5), 752–773 (2018).
pubmed: 29496798 doi: 10.1161/CIRCRESAHA.117.311081
Wodchis, W. P., Bhatia, R. S., Leblanc, K., Meshkat, N. & Morra, D. A review of the cost of atrial fibrillation. Value Health 15(2), 240–248 (2012).
pubmed: 22433754 doi: 10.1016/j.jval.2011.09.009
Heijman, J., Voigt, N., Nattel, S. & Dobrev, D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ. Res. 114(9), 1483–1499 (2014).
pubmed: 24763466 doi: 10.1161/CIRCRESAHA.114.302226
Burstein, B. & Nattel, S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 51(8), 802–809 (2008).
pubmed: 18294563 doi: 10.1016/j.jacc.2007.09.064
Wakili, R., Voigt, N., Kaab, S., Dobrev, D. & Nattel, S. Recent advances in the molecular pathophysiology of atrial fibrillation. J. Clin. Invest. 121(8), 2955–2968 (2011).
pubmed: 21804195 pmcid: 3148739 doi: 10.1172/JCI46315
Andrade, J., Khairy, P., Dobrev, D. & Nattel, S. The clinical profile and pathophysiology of atrial fibrillation: Relationships among clinical features, epidemiology, and mechanisms. Circ. Res. 114(9), 1453–1468 (2014).
pubmed: 24763464 doi: 10.1161/CIRCRESAHA.114.303211
Asghar, O. et al. Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Curr. Cardiol. Rev. 8(4), 253–264 (2012).
pubmed: 22920475 pmcid: 3492809 doi: 10.2174/157340312803760749
Guo, Y., Lip, G. Y. & Apostolakis, S. Inflammation in atrial fibrillation. J. Am. Coll. Cardiol. 60(22), 2263–2270 (2012).
pubmed: 23194937 doi: 10.1016/j.jacc.2012.04.063
Samman Tahhan, A. et al. Association between oxidative stress and atrial fibrillation. Heart Rhythm 14(12), 1849–1855 (2017).
pubmed: 28757307 doi: 10.1016/j.hrthm.2017.07.028
Nattel, S. New ideas about atrial fibrillation 50 years on. Nature 415(6868), 219–226 (2002).
pubmed: 11805846 doi: 10.1038/415219a
Mayr, M. et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J. Am. Coll. Cardiol. 51(5), 585–594 (2008).
pubmed: 18237690 doi: 10.1016/j.jacc.2007.09.055
Barallobre-Barreiro, J. et al. Glycoproteomics reveals decorin peptides with anti-myostatin activity in human atrial fibrillation. Circulation 134(11), 817–832 (2016).
pubmed: 27559042 pmcid: 5081096 doi: 10.1161/CIRCULATIONAHA.115.016423
Zhang, P. et al. Protein analysis of atrial fibrosis via label-free proteomics in chronic atrial fibrillation patients with mitral valve disease. PLoS ONE 8(4), e60210 (2013).
pubmed: 23593175 pmcid: 3617171 doi: 10.1371/journal.pone.0060210
Nauseef, W. M. Myeloperoxidase in human neutrophil host defence. Cell Microbiol. 16(8), 1146–1155 (2014).
pubmed: 24844117 pmcid: 4301731 doi: 10.1111/cmi.12312
Reimand, J. et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA Cytoscape and EnrichmentMap. Nat Protoc 14(2), 482–517 (2019).
pubmed: 30664679 pmcid: 6607905 doi: 10.1038/s41596-018-0103-9
Xiao, Y. et al. A novel significance score for gene selection and ranking. Bioinformatics 30(6), 801–807 (2014).
pubmed: 22321699 doi: 10.1093/bioinformatics/btr671
Papayannopoulos, V. Neutrophil extracellular traps in immunity and disease. Nat. Rev. Immunol. 18(2), 134–147 (2018).
pubmed: 28990587 doi: 10.1038/nri.2017.105
Wang, S. et al. S100A8/A9 in inflammation. Front. Immunol. 9, 1298 (2018).
pubmed: 29942307 pmcid: 6004386 doi: 10.3389/fimmu.2018.01298
Walton, G. M. et al. Repurposing treatments to enhance innate immunity. Can statins improve neutrophil functions and clinical outcomes in COPD?. J. Clin. Med. 5, 10 (2016).
doi: 10.3390/jcm5100089
Al-Ani, B. Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide. Saudi Med. J. 34(5), 477–483 (2013).
pubmed: 23677263
Gaul, D. S., Stein, S. & Matter, C. M. Neutrophils in cardiovascular disease. Eur. Heart J. 38(22), 1702–1704 (2017).
pubmed: 30052884 doi: 10.1093/eurheartj/ehx244
Weymann, A. et al. Prediction of new-onset and recurrent atrial fibrillation by complete blood count tests: A comprehensive systematic review with meta-analysis. Med. Sci. Monit. Basic Res. 23, 179–222 (2017).
pubmed: 28496093 pmcid: 5439535 doi: 10.12659/MSMBR.903320
Ertas, G. et al. Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. J. Neurol. Sci. 324(1–2), 49–52 (2013).
pubmed: 23084070 doi: 10.1016/j.jns.2012.09.032
Rudolph, V. et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat. Med. 16(4), 470–474 (2010).
pubmed: 20305660 pmcid: 2880896 doi: 10.1038/nm.2124
Li, S. B. et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J. Investig. Med. 61(4), 722–727 (2013).
pubmed: 23392057 doi: 10.2310/JIM.0b013e3182857fa0
Xu, G. et al. Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J. Biol. Chem. 287(7), 4808–4817 (2012).
pubmed: 22117066 doi: 10.1074/jbc.M111.275719
Chua, F. & Laurent, G. J. Neutrophil elastase: Mediator of extracellular matrix destruction and accumulation. Proc. Am. Thorac. Soc. 3(5), 424–427 (2006).
pubmed: 16799086 doi: 10.1513/pats.200603-078AW
Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell. Biol. 8(3), 221–233 (2007).
pubmed: 17318226 pmcid: 2760082 doi: 10.1038/nrm2125
Reilly, C. F., Tewksbury, D. A., Schechter, N. M. & Travis, J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J. Biol. Chem. 257(15), 8619–8622 (1982).
pubmed: 6807977 doi: 10.1016/S0021-9258(18)34171-1
Rykl, J. et al. Renal cathepsin G and angiotensin II generation. J. Hypertens. 24(9), 1797–1807 (2006).
pubmed: 16915029 doi: 10.1097/01.hjh.0000242404.91332.be
Massberg, S. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med. 16(8), 887–896 (2010).
pubmed: 20676107 doi: 10.1038/nm.2184
Kominsky, D. J., Campbell, E. L. & Colgan, S. P. Metabolic shifts in immunity and inflammation. J. Immunol. 184(8), 4062–4068 (2010).
pubmed: 20368286 doi: 10.4049/jimmunol.0903002
Ausma, J. et al. Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fibrillation. Cardiovasc. Res. 47(4), 788–796 (2000).
pubmed: 10974227 doi: 10.1016/S0008-6363(00)00139-5
Malicki, J. J. & Johnson, C. A. The cilium: Cellular antenna and central processing unit. Trends Cell. Biol. 27(2), 126–140 (2017).
pubmed: 27634431 pmcid: 5278183 doi: 10.1016/j.tcb.2016.08.002
Kawasaki, M. et al. TGF-beta suppresses Ift88 expression in chondrocytic ATDC5 cells. J. Cell Physiol. 230(11), 2788–2795 (2015).
pubmed: 25828538 doi: 10.1002/jcp.25005
Saigusa, T. et al. Activation of the intrarenal renin-angiotensin-system in murine polycystic kidney disease. Physiol. Rep. 3, 5 (2015).
doi: 10.14814/phy2.12405
Villalobos, E. et al. Fibroblast primary cilia are required for cardiac fibrosis. Circulation 139(20), 2342–2357 (2019).
pubmed: 30818997 pmcid: 6517085 doi: 10.1161/CIRCULATIONAHA.117.028752
Zimmerman, K. A., Song, C. & Yoder, B. K. Primary cilia regulate accumulation of innate and adaptive immune cells following injury. J. Immunol. 198, 1 (2017).
doi: 10.4049/jimmunol.198.Supp.221.5
Sung, C. H. & Leroux, M. R. The roles of evolutionarily conserved functional modules in cilia-related trafficking. Nat. Cell. Biol. 15(12), 1387–1397 (2013).
pubmed: 24296415 pmcid: 4016715 doi: 10.1038/ncb2888
Rao, Y., Hao, R., Wang, B. & Yao, T. P. A Mec17-myosin II effector axis coordinates microtubule acetylation and actin dynamics to control primary cilium biogenesis. PLoS ONE 9(12), e114087 (2014).
pubmed: 25494100 pmcid: 4262394 doi: 10.1371/journal.pone.0114087
Hong, H., Kim, J. & Kim, J. Myosin heavy chain 10 (MYH10) is required for centriole migration during the biogenesis of primary cilia. Biochem. Biophys. Res. Commun. 461(1), 180–185 (2015).
pubmed: 25881509 doi: 10.1016/j.bbrc.2015.04.028
Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685–1695 (2005).
pubmed: 15843671 doi: 10.1056/NEJMra043430
van den Berg, N. W. E. et al. PREventive left atrial appenDage resection for the predICtion of fuTure atrial fibrillation: Design of the PREDICT AF study. J. Cardiovasc. Med. (Hagerstown) 20(11), 752–761 (2019).
doi: 10.2459/JCM.0000000000000868
Sabrkhany, S. et al. Exploration of the platelet proteome in patients with early-stage cancer. J. Proteom. 177, 65–74 (2018).
doi: 10.1016/j.jprot.2018.02.011
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26(12), 1367–1372 (2008).
pubmed: 19029910 doi: 10.1038/nbt.1511
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 47(D1), D442–D450 (2019).
pubmed: 30395289 doi: 10.1093/nar/gky1106
Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 8(8), 1551–1566 (2013).
pubmed: 23868073 pmcid: 6519453 doi: 10.1038/nprot.2013.092
Szklarczyk, D. et al. The STRING database in 2017: Quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 45(D1), D362–D368 (2017).
pubmed: 27924014 doi: 10.1093/nar/gkw937
Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498–2504 (2003).
pubmed: 14597658 pmcid: 403769 doi: 10.1101/gr.1239303
Ramakers, C., Ruijter, J. M., Deprez, R. H. & Moorman, A. F. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci. Lett. 339(1), 62–66 (2003).
pubmed: 12618301 doi: 10.1016/S0304-3940(02)01423-4
Pham, T. V., Piersma, S. R., Warmoes, M. & Jimenez, C. R. On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics 26(3), 363–369 (2010).
pubmed: 20007255 doi: 10.1093/bioinformatics/btp677
R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ .

Auteurs

Makiri Kawasaki (M)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Eva R Meulendijks (ER)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Nicoline W E van den Berg (NWE)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Fransisca A Nariswari (FA)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Jolien Neefs (J)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Robin Wesselink (R)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Sarah W E Baalman (SWE)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Aldo Jongejan (A)

Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Bioinformatics Laboratory, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Tim Schelfhorst (T)

OncoProteomics Laboratory, Amsterdam UMC, Cancer Centre Amsterdam, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Sander R Piersma (SR)

OncoProteomics Laboratory, Amsterdam UMC, Cancer Centre Amsterdam, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Thang V Pham (TV)

OncoProteomics Laboratory, Amsterdam UMC, Cancer Centre Amsterdam, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Wim J P van Boven (WJP)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Antoine H G Driessen (AHG)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Connie R Jimenez (CR)

OncoProteomics Laboratory, Amsterdam UMC, Cancer Centre Amsterdam, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Joris R de Groot (JR)

Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. j.r.degroot@amsterdamumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH